The study of intraperitoneal hyperthermic perfusion chemotherapy combined with traditional Chinese medicine on survival status after laparoscopic ovarian cancer reduction surgery
- Conditions
- Ovarian cancer
- Registration Number
- ITMCTR2100004746
- Lead Sponsor
- Chengdu Women's and Children's Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- Not specified
1) Initial treatment of ovarian cancer (including rare types of ovarian tumors);
2) Used for neoadjuvant chemotherapy and second HIPEC after intermittent cytoreductive surgery.
3) Patients with epithelial ovarian cancer diagnosed by postoperative histopathology;
4) Estimated survival time >= 6 months;
5) Informed consent of the patient and family members, and signed informed consent form for hyperthermic perfusion.
1) Intestinal obstruction, extensive adhesions in the peritoneal cavity, and obvious inflammation in the abdominal cavity;
2) There may be a high risk of poor postoperative anastomotic healing;
Factors, including anastomotic tissue edema, ischemia, obvious tension, severe hypoproteinemia, etc.;
3) Major organ dysfunction such as heart, kidney, liver, and brain;
4) Severe coagulation dysfunction; bile obstruction and ureteral obstruction;
5) Aged >= 75 years old is a relative contraindication.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of Life;
- Secondary Outcome Measures
Name Time Method Imaging data;Tumor markers;Drug side effects;